Journal of Rheumatology Publishes Manuscript on Scientific Study of Celadrin™, a Natural-Based Product for Joint Function and Mobility

Results from a clinical trial by San Diego based Imagenetix, Inc. (Symbol: IAGX) suggest that its product Celadrin™, a natural-based nutritional supplement comprised of a combination of cetylated fatty acids, promotes optimal joint health.* Data from the clinical trial is published in the August, 2002 issue of the Journal of Rheumatology.

In a double-blind, multi-center, placebo-controlled clinical trial of Celadrin™, researchers examined the impact of a 68-day oral administration of Celadrin™ on 64 participants who were experiencing joint and mobility challenges. The placebo group and the Celadrin™ group were evaluated at baseline, at 30 days, and at 68 days. Among other measurements, evaluations included physician assessment, knee range of motion, and the Lequesne algofunctional index.

Results after 68 days indicated that participants treated with Celadrin™ exhibited healthy joint mobility, flexibility and function* compared to those given the placebo. Participants responses to the Lequesne index indicated a statistically significant (p<0.001) shift towards functional improvement for the Celadrin™ group after 68 days compared to the participants given the placebo.

Data from the study indicated that Celadrin™ not only promoted joint flexibility, but significantly improved the reported ability of participants to walk long distances. Moreover, participants in the study exhibited no side effects.

"The scientific findings are very significant," said Imagenetix Director of Research and Development, Robert Hesslink, Jr., Sc.D. "We are very pleased that the Journal of Rheumatology published the findings enabling the data to be viewed by top medical and scientific professionals throughout the world."

"Our goal is to make this exceptional product, Celadrin™, available to all the millions of people who can benefit from it," said Bill Spencer, President of Imagenetix. "Celadrin™ is unique. It does not contain Glucosamine, Chondroitin, MSM, or SAMe. Additionally, unlike many competitive products, with over 90,000,000 Celadrin™ pills distributed to date, we have no evidence of reported side effects. Safe and effective products, available at a reasonable cost and backed up by solid scientific research continue to be a consumer priority. Celadrin™ satisfies all of those criteria."

About Celadrin™

Celadrin™ is a safe and effective, natural nutritional supplement developed by Imagenetix. It is a natural-based supplement comprised of a blend of cetylated fatty acids, intended to support healthy joint function and mobility*.

The current scientific research reported in the Journal of Rheumatology adds to Celadrin’s™ scientific success in supporting optimal joint health, including both function and mobility.*

Celadrin™ cream, a topical rub, is currently being subjected to a clinical trial. Celadrin™ cream with menthol is currently being marketed as an OTC pain relieving product.

About Imagenetix, Inc.

San Diego-based Imagenetix, Inc., (Symbol: IAGX), is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to address specific health issues on a global basis. The Company develops, formulates, private-labels and co-brands proprietary and leading-edge nutritional and skin care products to be marketed by distributors globally through multiple channels of distribution.

Safe Harbor Statement

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.

Media note: For copies of previous research on Celadrin™, or to schedule an interview, please contact Tara Heisler at Media Relations, Inc. at (800) 999-4859 x 210.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.